Linical Co 2183.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 2183.T. It has been listed since 27 October 2008. In the fiscal year to 31 March 2026, it reported revenue of ¥8.67bn and a net loss of ¥3.33bn. At that date it held total assets of ¥12.00bn and shareholders' equity of ¥3.98bn.

Linical Co., Ltd. engages in pharmaceutical contract research projects providing consulting, monitoring, and quality control services to pharmaceutical companies. The company is headquartered in Osaka, Osaka-Fu. The company went IPO on 2008-10-27. The firm operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Kazuhiro HatanoPresident, Executive President, CEO, CCO, Chief Director of Development, Director of Ikuyaku BU in Main Development Unit, Manager of Sales Planning Office, Representative Director, since 2010
• Mr. Akihiro TakahashiExecutive Officer, Chief Financial Officer, Manager of Accounting & Finance Unit, since 2007
• Dr. Toshiaki NagafujiExecutive Officer, Chief Technical Officer, Director of Drug Discovery Support in Main Development Unit
• Mr. Jun KawaiExecutive Officer, Chief Administrative Officer, Manager of General Affairs, Human Resources and Legal Affairs Unit, since 2008
• Mr. Masayoshi TokunoExecutive Officer, Chief Information Officer, Manager of Global IT Strategy Office
• Ms. Shiori YamaguchiExecutive Officer, Chief Compliance Officer, Manager of Audit Office, since 2009
• Mr. Tomoko InomataExecutive Officer, Director of Primary Area Business in Main Development Unit
• Mr. Masaya MiyazakiExecutive Officer, Chief Asia Pacific Officer, since 2007
• Mr. Isao SakamotoExecutive Officer, CSO (Chief Strategy Officer), Director of Central Nervous System Business in Main Development Unit, Manager of Business Planning Office, since 2007
• Mr. Tatsuya ShiraishiExecutive Officer
• Mr. Yushi TajimaExecutive Officer
• Mr. Satoru ToyodaExecutive Officer, Director of Oncology Business in Main Development Unit

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.